netFormulary NHS
NHS NEL
Demonstration Formulary
 Search
 Formulary Chapter 6: Endocrine system - Full Chapter
Notes:

 

 

 

Chapter Links...
 Details...
06.04.01.02  Expand sub section  Progestogens
Medroxyprogesterone Acetate (Climanor®)
View adult BNF View SPC online View childrens BNF
Formulary
Green
 
 
Medroxyprogesterone Acetate (Depo -Provera®)
View adult BNF View SPC online View childrens BNF
Formulary
Green
 
 
Medroxyprogesterone Acetate (Provera®)
View adult BNF View SPC online View childrens BNF
Formulary
Green
 
 
Medroxyprogesterone Acetate (Sayana press®)
View adult BNF View SPC online View childrens BNF
Formulary
Green

Suitable for self injection in patients who have had appropriate tranining

 
 
Progesterone
(Pessary)
View adult BNF View SPC online View childrens BNF
Formulary
Amber Initiation

    BRANDS

  • Cyclogest pessary 
  • Lutigest pessary 
 
 
Progesterone (micronised) (Utrogestan ®)
View adult BNF View SPC online View childrens BNF
Formulary
Green
 
 
 ....
 Non Formulary Items
Dydrogesterone  (Duphaston®)

View adult BNF View SPC online View childrens BNF
Non Formulary
Dysrogesterone  (Duphaston® HRT)

View adult BNF View SPC online View childrens BNF
Non Formulary
Black
Norethisterone  (Micronor®HRT)

View adult BNF View SPC online View childrens BNF
Non Formulary
Progesterone Injection  (Gestone®)

View adult BNF View SPC online View childrens BNF
Non Formulary
Ulipristal acetate  (Esmya®)

View adult BNF View SPC online View childrens BNF
Non Formulary
Black

MHRA March 2020 Esmya (ulipristal acetate): suspension of the licence due to risk of serious liver injury

July 2018 - Traffic light status amended to RED in light of EMA update

Esmya: new measures to minimise risk of rare but serious liver injury

The only indication approved for use by the APC is
pre-operative treatment of moderate to severe symptoms of uterine fibroids (1 course).

Link  EMA June 2018: Esmya: new measures to minimise risk of rare but serious liver injury
Link  MHRA February 2018: Esmya (ulipristal acetate) for uterine fibroids: do not initiate or re-start treatment; monitor liver function in current and recent users
  
Key
Restricted Drug Restricted Drug
Unlicensed Drug Unlicensed
click to search medicines.org.uk
Link to adult BNF
click to search medicines.org.uk
Link to children's BNF
click to search medicines.org.uk
Link to SPCs
Cytotoxic Drug
Cytotoxic Drug
CD
Controlled Drug
High Cost Medicine
High Cost Medicine
Cancer Drugs Fund
Cancer Drugs Fund
NHSE
NHS England
Homecare
Homecare
ICB
ICB
Green Low Carbon

Low carbon footprint

Amber Medium Carbon

Medium carbon footprint

Red High carbon footprint

High carbon footprint

Status Description

Green

Medicines which are suitable for initiation and maintenance prescribing by primary and secondary care clinicians. These medicines should be initiated and prescribed within their licensed indications  

Amber Initiation

Amber Specialist Initiation: Initiation and maintenance of prescribing by Specialists and transfer to Primary Care prescribing when appropriate. This may be supported by a RICaD, annotated within the formulary entry.  

Amber SC

Amber Shared Care: Initiation and maintenance of prescribing by Specialists and transfer to Primary Care prescribing, in accordance with an ESCA, annotated within the formulary entry.  

Amber Recommended

Amber Specialist Recommendation: Initiation and maintenance of prescribing in Primary Care following recommendation from a specialist.  

Red

Medicines for initiation and maintenance prescribing by Specialists (hospital or GPs with Special Interest) only  

Grey

Positive NICE TA and /or awaiting local clarification on place in therapy; Please contact your Medicines Optimisation team for more information.  

Black

Non-formulary Medicines which APC/Trust DTC has actively reviewed and do not recommend for use.  

Multiple

Check Notes as varies across the area  

netFormulary